Département de Pathologie, Assistance Publique Hôpitaux de Paris, Groupe Hospitalier Henri Mondor, Créteil, France; Inserm U955, Team 18, Créteil, France; Université Paris-Est Créteil, France; INSERM UMR_S1138, Centre de Recherche des Cordeliers, Equipe cancer et immunité anti-tumorale, 15 rue de l'Ecole de Médecine, F75006 Paris, France.
INSERM UMR_S1138, Centre de Recherche des Cordeliers, Equipe cancer et immunité anti-tumorale, 15 rue de l'Ecole de Médecine, F75006 Paris, France; Programme Cartes d'Identité des Tumeurs, Ligue Nationale Contre le Cancer, Paris, France.
J Hepatol. 2019 Jan;70(1):58-65. doi: 10.1016/j.jhep.2018.09.003. Epub 2018 Sep 11.
BACKGROUND & AIMS: Tertiary lymphoid structures (TLSs) provide a local and critical microenvironment for generating anti-tumor cellular and humoral immune responses. TLSs are associated with improved clinical outcomes in most solid tumors investigated to date. However, their role in hepatocellular carcinoma (HCC) is debated, as they have recently been shown to promote the growth of malignant hepatocyte progenitors in the non-tumoral liver.
We aimed to determine, by pathological review, the prognostic significance of both intra-tumoral and non-tumoral TLSs in a series of 273 patients with HCC treated by surgical resection in Henri Mondor University Hospital. Findings were further validated by gene expression profiling using a public data set (LCI cohort).
TLSs were identified in 47% of the tumors, by pathological review, with lymphoid aggregates, primary and secondary follicles in 26%, 16% and 5% of the cases, respectively. Univariate and multivariate analyses showed that intra-tumoral TLSs significantly correlated with a lower risk of early relapse (<2 years after surgery, hazard ratio 0.46, p = 0.005). Interestingly, the risk of recurrence was also related to the degree of TLS maturation (primary or secondary follicles vs. lymphoid aggregates, p = 0.01). A gene expression signature associated with the presence of intra-tumoral TLS was also independently associated with a lower risk of early relapse in the LCI cohort. No association between the density of TLSs located in the adjacent non-tumoral liver and early or late recurrence was observed.
We have shown that intra-tumoral TLSs are associated with a lower risk of early relapse in 2 independent cohorts of patients with HCC treated by surgical resection. Thus, intra-tumoral TLSs may reflect the existence of ongoing, effective anti-tumor immunity.
Tertiary lymphoid structures provide a critical microenvironment for generating anti-tumor immune responses, and are associated with improved clinical outcome in most cancers investigated. Their role in hepatocellular carcinoma is however debated. We show in the present study that intra-tumoral tertiary lymphoid structures are associated with a low risk of early relapse after surgical resection, suggesting that they reflect the existence of in situ, effective anti-tumor immunity.
三级淋巴结构 (TLS) 为产生抗肿瘤细胞和体液免疫反应提供了局部和关键的微环境。迄今为止,大多数研究的实体瘤都表明 TLS 与改善的临床结果相关。然而,它们在肝细胞癌 (HCC) 中的作用存在争议,因为最近的研究表明它们促进了非肿瘤性肝脏中恶性肝细胞前体的生长。
我们旨在通过病理回顾,确定 Henri Mondor 大学医院 273 例接受手术切除治疗的 HCC 患者系列中肿瘤内和非肿瘤性 TLS 的预后意义。使用公共数据集 (LCI 队列) 通过基因表达谱进一步验证了这些发现。
通过病理回顾,在 47%的肿瘤中发现了 TLS,其中淋巴聚集物、原发性和次级滤泡分别占 26%、16%和 5%的病例。单因素和多因素分析表明,肿瘤内 TLS 与早期复发的风险显著降低相关(手术后 2 年内,危险比 0.46,p=0.005)。有趣的是,复发的风险也与 TLS 成熟程度相关(原发性或次级滤泡与淋巴聚集物相比,p=0.01)。与肿瘤内 TLS 存在相关的基因表达特征也与 LCI 队列中早期复发的风险降低独立相关。在相邻非肿瘤性肝脏中 TLS 密度与早期或晚期复发之间没有观察到相关性。
我们表明,在接受手术切除治疗的 2 个独立 HCC 患者队列中,肿瘤内 TLS 与早期复发风险降低相关。因此,肿瘤内 TLS 可能反映了持续存在的有效抗肿瘤免疫。
三级淋巴结构为产生抗肿瘤免疫反应提供了关键的微环境,并且在大多数研究的癌症中与改善的临床结果相关。然而,它们在肝细胞癌中的作用存在争议。我们在本研究中表明,肿瘤内三级淋巴结构与手术后早期复发风险降低相关,表明它们反映了原位有效抗肿瘤免疫的存在。